Porous aerosil loading probucol using supercritical carbon dioxide: Preparation, in vitro and in vivo characteristics

Pharmaceutical Development and Technology

Volumn 19, Issue 4, 2014, Pages 501-506

  Chu, Chunxia ^a   Liu, Muhua ^a   Wang, Dongmei ^a   Guan, Jibin ^a   Cai, Cuifang ^a   Sun, Yuanpeng ^a   Zhang, Tianhong ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Aerosil; Bioavailability; Dissolution; Physicochemistry property; Probucol; Supercritical carbon dioxide

Indexed keywords

AEROSIL; CARBON DIOXIDE; CARBOXYMETHYLSTARCH SODIUM; LACTOSE; PROBUCOL;

ADSORPTION; ANIMAL EXPERIMENT; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; NONHUMAN; PHYSICAL CHEMISTRY; POWDER; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUPERCRITICAL FLUID; TABLET; TABLET COMPRESSION; X RAY POWDER DIFFRACTION;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBON DIOXIDE; DOGS; POROSITY; POWDERS; PROBUCOL; SILICON DIOXIDE; SOLUBILITY; TABLETS;

EID: 84899943968     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.800109     Document Type: Article

References (24)

1. Shudo J, Pongpeerapat A,Wanawongthai C, et al. In vivo assessment of oral administration of probucol nanoparticles in rats. Biol Pharm Bull 2008;31:321-325.
2. Benson GM, Schiffelers R, Nicols C, et al. Effect of probucol on serum lipids, atherosclerosis and toxicology in fat-fed LDL receptor deficientmice. Atherosclerosis 1998;141:237-247.
3. Yamashita S, Matsuzawab Y. Where are we with probucol: a new life for an old drug? Atherosclerosis 2009;207:16-23.
4. Kubo Y, Terashima Y, Yagi N, et al. Enhanced bioavailability of probucol following the administration of solid dispersion systems of probucol- polyvinylpyrrolidone in rabbits. Biol Pharm Bull 2009;32: 1880-1884.
5. Hijrter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Delivery Rev 1997;25:3-14.
6. Zaitseva TM, Lupanov VP, Lyakishev AA, et al. Pharmacokinetics of probucol dosage forms in clinical tests. Pharm Chem J 1995;29:21-23.
7. Io T, Fukami T, Yamamoto K, et al. Homogeneous nanoparticles to enhance the efficiency of ahydrophobic drug, anti-hyperlipidemic Probucol, characterized by solid-state NMR. Mol Pharm 2010;7:1-12.
8. Wanawongthai C, Pongpeerapat A, Higashi K, et al. Nanoparticle formation from probucol/PVP/sodiumalkyl sulfate co-groundmixture. Int J Pharm 2009;376:169-175.
9. Broman E, Khoo C, Taylor LS. A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug. Int J Pharm 2001;222:139-151.
10. Sha XY, Wu J, Chen YZ, Fang XL. Self-microemulsifying drugdelivery system for improved oral bioavailability of probucol: preparation and evaluation. Int J Nanomed 2012;7:705-712.
11. Nielsen FS, Petersen KB, Mullertz A. Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of dropletsize and dietary state. Eur J Pharm Biopharm 2008;69: 553-562.
12. Badens E, Magnan C, Charbit G. Microparticles of soylecithin formed By supercritical processes. Biotechnol Bioeng 2001;72: 194-204.
13. Tom JW, Debenedetti PG. Formation of bioerodible polymeric microspheres and microparticles by rapid expansion of supercritical solutions. Biotechnol Prog 1991;7:403-411.
14. Fages J, Lochard H, Letourneau JJ, et al. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Technol 2004;141:219-226.
15. Chiou AHJ, Yeh MK, Changyi Ch, Dapeng W. Micronization of meloxicam using a supercritical fluids process. J Supercrit Fluids 2007;42:120-128.
16. Friedrich H, Fussnegger B, Kolter K, Bodmeier R. Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers. Eur J Pharm Biopharm 2006;62:171-177.
17. Miura H, Kanebako M, Shirai H, et al. Enhancement of dissolution rate and oral absorption of a poorly water-soluble drug, K-832, by adsorption onto porous silica using supercritical carbon dioxide. Eur J Pharm Biopharm 2010;76:215-221.
18. VanNijlen T, Brennan K, VandenMooter G, et al. Improvement of the dissolution rate of artemisinin by means of supercritical fluid technology and solid dispersions. Int J Pharm 2003;254:173-181.
19. Sanganwar GP, Gupta RB. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. Int J Pharm 2008;360:213-218.
20. Guenther U, Smirnova I, Neubert RH. Hydrophilic silica aerogels as dermal drug delivery systems - dithranol as amodel drug. Eur J Pharm Biopharm 2008;69:935-942.
21. Pikal MJ, Lukes AL, Lang JE, Gaines K. Quantative crystallinity determinations for b-lactam antibiotics by solution calorimetry: correlation with stability. J Pharm Sci 1978;67:767-773.
22. Gerber JJ, Caira MR, Lotter AP. Structures of two conformational polymorphs of the cholesterol-lowering drug probucol. J Cryst Spectrosc Res 1993;23:863-869.
23. Marsac PJ, Li T, Taylor LS. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res 2009;26:139-11.
24. Marsac PJ, Shamblin SL, Taylor LS. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 2006;23:2417-2426.